Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 304, Issue 10, 2013, Pages

  Preston, Ioana R ^a   Sagliani, Kristen D ^a   Warburton, Rod R ^a   Hill, Nicholas S ^a   Fanburg, Barry L ^a   Jaffe, Iris Z ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Hypoxia; Monocrotaline; Pulmonary vascular remodeling; Spironolactone

Indexed keywords

ALDOSTERONE; MEDIUM CHAIN TRIACYLGLYCEROL; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; MONOCROTALINE; PLATELET DERIVED GROWTH FACTOR; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; ESTROGEN RESPONSIVE ELEMENT; HEART HEMODYNAMICS; HEART INDEX; HEART MUSCLE CELL; HEART OUTPUT; HISTOLOGY; IMMUNOFLUORESCENCE; LUNG BLOOD VESSEL; LUNG VASCULAR RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; TRANSCRIPTION INITIATION;

ALDOSTERONE; HYPOXIA; MONOCROTALINE; PULMONARY VASCULAR REMODELING; SPIRONOLACTONE;

ALDOSTERONE; ANIMALS; ANOXIA; ARTERIAL PRESSURE; BODY WEIGHT; CARDIAC OUTPUT; CELL PROLIFERATION; FIBROSIS; HEART VENTRICLES; HYPERTENSION, PULMONARY; MICE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCYTES, SMOOTH MUSCLE; PLATELET-DERIVED GROWTH FACTOR; PULMONARY ARTERY; RATS; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; VASCULAR RESISTANCE; VENTRICULAR REMODELING;

EID: 84878652861     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00300.2012     Document Type: Article

References (42)

1. Arjona AA, Hsu CA, Wrenn DS, Hill NS. Effects of natriuretic peptides on vascular smooth-muscle cells derived from different vascular beds. Gen Pharmacol 28: 387-392, 1997.
2. Badesch DB, Lee PD, Parks WC, Stenmark KR. Insulin-like growth factor I stimulates elastin synthesis by bovine pulmonary arterial smooth muscle cells. Biochem Biophys Res Commun 160: 382-387, 1989.
3. Bear MD, Li M, Liu Y, Giel-Moloney MA, Fanburg BL, Toksoz D. The Lbc Rho guanine nucleotide exchange factor alpha-catulin axis functions in serotonin-induced vascular smooth muscle cell mitogenesis and RhoA/ROCK activation. J Biol Chem 285: 32919-32926, 2010.
4. Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 17: 1152-1156, 1997.
5. Cahill E, Rowan SC, Sands M, Banahan M, Ryan D, Howell K, McLoughlin P. The pathophysiological basis of chronic hypoxic pulmonary hypertension in the mouse: vasoconstrictor and structural mechanisms contribute equally. Exp Physiol 97: 796-806, 2012.
6. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 102: 1359-1367, 2008.
7. Chabot A, Jiang BH, Shi Y, Tardif JC, Dupuis J. Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure (Abstract). BMC Cardiovasc Disord 11: 72, 2011.
8. Chintalgattu V, Ai D, Langley RR, Zhang J, Bankson JA, Shih TL, Reddy AK, Coombes KR, Daher IN, Pati S, Patel SS, Pocius JS, Taffet GE, Buja LM, Entman ML, Khakoo AY. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest 120: 472-484, 2010.
9. de Man FS, Tu L, Handoko ML, Rain S, Ruiter G, Francois C, Schalij I, Dorfmuller P, Simonneau G, Fadel E, Perros F, Boonstra A, Postmus PE, van der Velden J, Vonk-Noordegraaf A, Humbert M, Eddahibi S, Guignabert C. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med 186: 780-789, 2012.
10. Frieler RA, Meng H, Duan SZ, Berger S, Schutz G, He Y, Xi G, Wang MM, Mortensen RM. Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia. Stroke 42: 179-185, 2011.
11. Fulton RM, Hutchinson EC, Jones AM. Ventricular weight in cardiac hypertrophy. Br Heart J 14: 413-420, 1952.
12. Hislop A, Reid L. New findings in pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. Br J Exp Pathol 57: 542-554, 1976.
13. http://www.clinicaltrials.gov/ct2/show/NCT01712620?term_spironolactone_ pulmonary_hypertension&rank_3. Spironolactone for Pulmonary Arterial Hypertension. NCT01712620, edited by NIHCC, 2012.
14. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 96: 643-650, 2005.
15. Jaffe IZ, Newfell BG, Aronovitz M, Mohammad NN, McGraw AP, Perreault RE, Carmeliet P, Ehsan A, Mendelsohn ME. Placental growth factor mediates aldosterone-dependent vascular injury in mice. J Clin Invest 120: 3891-3900, 2010.
16. Jaffe IZ, Tintut Y, Newfell BG, Demer LL, Mendelsohn ME. Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol 27: 799-805, 2007.
17. Koskenvuo JW, Mirsky R, Zhang Y, Angeli FS, Jahn S, Alastalo TP, Schiller NB, Boyle AJ, Chatterjee K, De Marco T, Yeghiazarians Y. A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model. Int J Cardiovasc Imaging 26: 509-518, 2010.
18. Maron BA, Opotowsky AR, Landzberg MJ, Loscalzo J, Waxman AB, Leopold JA. Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. Eur J Heart Fail 15: 277-283, 2013.
19. Maron BA, Zhang YY, White K, Chan SY, Handy DE, Mahoney CE, Loscalzo J, Leopold JA. Aldosterone inactivates the endothelin-b receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation 126: 963-974, 2012.
20. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 350: 256-265, 2012.
21. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance AM, Mendelsohn ME, Jaffe IZ. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 18: 1429-1433, 2012.
22. McGraw AP, Bagley J, Chen W-S, Galayda C, Nickerson H, Armani A, Caprio M, Carmeliet P, Jaffe IZ. Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. J Am Heart Assoc doi:10.1161/ JAHA.112.000018.
23. Medh RD, Schmidt TJ. Trans-retinoic acid and glucocorticoids synergistically induce transcription from the mouse mammary tumor virus promoter in human embryonic kidney cells. J Steroid Biochem Mol Biol 62: 129-142, 1997.
24. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, Schiffrin EL, Touyz RM. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redoxsensitive RhoA pathways. Arterioscler Thromb Vasc Biol 28: 1511-1518, 2008.
25. Newfell BG, Iyer LK, Mohammad NN, McGraw AP, Ehsan A, Rosano G, Huang PL, Mendelsohn ME, Jaffe IZ. Aldosterone regulates vascular gene transcription via oxidative stress-dependent and-independent pathways. Arterioscler Thromb Vasc Biol 31: 1871-1880, 2011.
26. Preston IR, Hill NS, Gambardella LS, Warburton RR, Klinger JR. Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. Exp Biol Med (Maywood) 229: 920-925, 2004.
27. Preston IR, Hill NS, Warburton RR, Fanburg BL. Role of 12-lipoxygenase in hypoxia-induced rat pulmonary artery smooth muscle cell proliferation. Am J Physiol Lung Cell Mol Physiol 290: L367-L374, 2006.
28. Sakurabayashi-Kitade S, Aoka Y, Nagashima H, Kasanuki H, Hagiwara N, Kawana M. Aldosterone blockade by Spironolactone improves the hypertensive vascular hypertrophy and remodeling in angiotensin II overproducing transgenic mice. Atherosclerosis 206: 54-60, 2009.
29. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821, 2005.
30. Schwenke DO, Pearson JT, Sonobe T, Ishibashi-Ueda H, Shimouchi A, Kangawa K, Umetani K, Shirai M. Role of Rho-kinase signaling and endothelial dysfunction in modulating blood flow distribution in pulmonary hypertension. J Appl Physiol 110: 901-908, 2011.
31. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD, Tuder RM. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 186: 261-272, 2012.
32. Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, Horiuchi M. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 26: 917-921, 2006.
33. Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, Wakimoto H, Nayor M, Konno T, Gorham JM, Wolf CM, Kim JB, Schmitt JP, Molkentin JD, Norris RA, Tager AM, Hoffman SR, Markwald RR, Seidman CE, Seidman JG. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J Clin Invest 120: 3520-3529, 2010.
34. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144: 275-285, 1994.
35. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schutz G, Lumeng CN, Mortensen RM. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 120: 3350-3364, 2010.
36. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 104: 467-472, 2001.
37. Weber KT, Brilla CG. Factors associated with reactive and reparative fibrosis of the myocardium. Basic Res Cardiol 87, Suppl 1: 291-301, 1992.
38. Weber KT, Brilla CG, Campbell SE. Regulatory mechanisms of myocardial hypertrophy and fibrosis: results of in vivo studies. Cardiology 81: 266-273, 1992.
39. Wilson DW, Segall HJ, Pan LC, Dunston SK. Progressive inflammatory and structural changes in the pulmonary vasculature of monocrotalinetreated rats. Microvasc Res 38: 57-80, 1989.
40. Wolf CM, Moskowitz IP, Arno S, Branco DM, Semsarian C, Bernstein SA, Peterson M, Maida M, Morley GE, Fishman G, Berul CI, Seidman CE, Seidman JG. Somatic events modify hypertrophic cardiomyopathy pathology and link hypertrophy to arrhythmia. Proc Natl Acad Sci USA 102: 18123-18128, 2005.
41. Yamanaka R, Otsuka F, Nakamura K, Yamashita M, Otani H, Takeda M, Matsumoto Y, Kusano KF, Ito H, Makino H. Involvement of the bone morphogenetic protein system in endothelin-and aldosteroneinduced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension. Hypertens Res 33: 435-445, 2010.
42. Yi ES, Kim H, Ahn H, Strother J, Morris T, Masliah E, Hansen LA, Park K, Friedman PJ. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med 162: 1577-1586, 2000.